1 Introduction
==============

The reproducibility of scientific results from multiple sources is critical to the establishment of scientific doctrine ([@bty675-B11]; [@bty675-B33]). The spread of these sources can occur over various domains, including temporal, geographical, and technological. From each of these domains, one can expect a degree of variation in results, attributable to the ambient laboratory environment or intrinsic qualities of the measurement device. In many cases, the degree of this variation exceeds that of what is expected, leading to a "crisis of reproducibility" ([@bty675-B3]; [@bty675-B5]; [@bty675-B29]) in science. These sources of variation are commonly known as the batch effect, particularly in genomics, and ameliorating methods exist for when it confounds the biological effect of interest across samples ([@bty675-B17]; [@bty675-B19]; [@bty675-B30]). However, an additional and less studied source of variation is that which occurs when an attempt is made to recapitulate results from a given technological platform on a subsequent platform, on the same set of samples and target loci. Platform-specific effects exist, and cross-platform studies ([@bty675-B13]; [@bty675-B14]; [@bty675-B20]; [@bty675-B28]; [@bty675-B35]; [@bty675-B43][@bty675-B42]; ) have been undertaken in order to characterise them. However, evaluation of concordance in these studies is mostly geared towards assessing relative performance of the technologies in question, and this is exemplified by associative metrics such as Venn diagrams of differentially expressed genes or pairwise coefficients of correlation. While informative, very little attention is given to evaluating the more fundamental trait of measurement quality. The reliability of a measurement not only influences the performance of the technology that occasioned it for scientific ends, but more practically it gives confidence to its operator of its fealty to the quantum of interest. A governing framework for the assessment of measurement robustness for a given suite of genomic technologies is absent from the current literature.

Since the turn of the $21^{st}$ century, genomic science has presented researchers with a choice of platforms on which to interrogate their biological samples, chief among them microarrays and sequencing technologies. The microarray revolutionised whole-genome science, especially in the field of transcriptomics, where the relative expression levels of most known genes could be profiled using high-throughput hybridisation techniques ([@bty675-B18]). Later, microarrays such as the Illumina Infinium HumanMethylation450 ([@bty675-B6]) and MethylationEPIC ([@bty675-B32]) were introduced to measure the levels of DNA methylation in human samples. The intensity of the fluorescent dye (indicating hybridisation levels) on RNA expression and DNA methylation microarray chips serves as the metric by which the genomic feature is measured. This is an analogue reading, and hence follows a continuous distribution.

In the last decade, high-throughput sequencing has replaced the microarray as the assay of choice for many researchers. Sequencing technologies such as RNA-Seq ([@bty675-B21]) and whole genome bisulfite sequencing (WGBS, [@bty675-B21], [@bty675-B22]) provide a richer set of biological information than microarrays, especially on anomalous features such as single nucleotide variations (SNVs) and alternative splicing events. In contrast to the analogue measurements of microarrays, sequencing measurements are represented digitally as a pileup of molecule counts per feature of interest. However, these still will not be an exact measure of the true level of the quantum of interest, since the shearing and subsequent sequencing of nucleic acid molecules produces a non-exhaustive sample from the population. Nucleic acid fragments compete for amplification within the assay, thus there is a stochastic component of the measurement for a given genomic feature (such as transcript abundance or methylation level of a CpG site).

Following the maxim of scientific reproducibility, genomic studies nevertheless aim to recapitulate the results derived from one technology on those from a subsequent platform. But what if this doesn't happen? To what do we ascribe the discrepancy? When confronted with a discordant result such as a low coefficient of correlation or a Venn diagram with poor overlap, the first instinct is to define a gold standard to which each deviant measurement can be compared. However, this is a dubious strategy in a number of ways. If the gold standard is chosen from one of the available platforms or protocols, a bias is immediately incurred, since error will be present in every measurement, regardless of its source.

Targeted approaches such as quantitative PCR (qPCR) and amplicon sequencing are accepted as more reliable, yet are impractical to assess from a genome-wide perspective due to constraints on time, reagents and nucleic acid yield. Furthermore, qPCR is still susceptible to amplification biases relating to sequence composition ([@bty675-B1]; [@bty675-B44]). Most alarmingly, thorough quality-control studies such as SEQC and MAQC ([@bty675-B35]; [@bty675-B36]) reveal systematic biases across assay sites for microarrays, qPCR and RNASeq, even with molecular-level quality control measures via ERCC spike-ins ([@bty675-B4]; [@bty675-B16]) taken for the latter. As such, the SEQC study concludes there is no single "gold standard" technology or strategy to which gene expression measurements ought to conform, and biases remain despite the best efforts made to standardise them.

Instead of defining a gold standard from existing or further laboratory work, we present an alternative by building a consensus on existing data, based upon non-additive linear modelling. The method described forthwith was elucidated by the late American statistician John Mandel ([@bty675-B24]; [@bty675-B26]), in order to characterise both within-laboratory and cross-laboratory traits from a suite of manufactured products. It is now recognised as a standard by the American Society for Testing and Materials (ASTM International) ([@bty675-B25]) for the identification of sources of variation and outliers from interlaboratory studies. Many variations on the interlaboratory test procedure exist (mostly summarised by [@bty675-B15]), but we restrict the application to that described in the ASTM standard, in particular the final equation in that publication (see Section 2).

The method described here is applied to the cross-platform case, with measurements from each platform represented by those from separate "laboratories". By finding common loci across a minimum of three platforms, we can characterise per-locus, per-platform sensitivity and precision, and compare the resulting distributions. In addition, we perform a true interlaboratory study measuring DNA fragment abundance using digital PCR (dPCR) ([@bty675-B45]), that evaluates measurement quality across testing sites. Given additional information from existing literature and platform annotation, we are then able to make valuable inferences about the susceptibility to bias of each platform that has contributed to the consensus.

2 Materials and methods
=======================

2.1 Approach
------------

We applied the row-linear model to four distinct genomic data sets: two measuring gene expression levels, one measuring DNA methylation levels and one measuring DNA fragment abundance. An individual row-linear model was fitted to each locus $k = 1,\ldots,G$ for the *G* loci common to all platforms/conditions in each dataset. For some of these datasets *G* is in the order of hundreds of thousands, resulting in over half a million row-linear models being fit for this study. A complete summary of the samples and platforms used, and loci tested, can be found in [Figure 1](#bty675-F1){ref-type="fig"}. In order for values to be made comparable, we use appropriate normalisations and transformations on each dataset (see Sample Sources and Preprocessing section in the [Supplementary Material](#sup1){ref-type="supplementary-material"}).

![Description of biological samples used in this study. Datasets are named T1 and T2(A, B) for transcription, M1 for methylation and IL1 for interlaboratory testing](bty675f1){#bty675-F1}

**Dataset T1** allows us to assess the genewise measurement quality of four platforms (three microarray platforms and one RNA-Seq) using 27 samples from The Cancer Genome Atlas glioblastoma multiforme (GBM) study ([@bty675-B41]).

**Dataset T2** is an in-house dataset with eight samples assessed over two more recently developed microarray platforms, and two separate RNA-Seq protocols. T2 was modelled at the gene locus (coding sequence) level, and then for T2A and T2B split into "probeset" levels according to annotation of the HuGene2.0st (HuGene) array and Human Transcriptome Array 2.0 (HTA) respectively. This was done for two reasons: firstly to fully interrogate the utility of these array platforms, and secondly to test whether a more granular summarisation of the datasets evinces subgenic trends. Both HuGene and HTA have targets summarising exonic or sub-exonic regions, over given genomic coordinates. These are characterised by the manufacturer as "probeset" level targets, whereas the gene-level summarisation is characterised as the "core" level. HuGene probeset targets are predominantly sub-exonic, whereas HTA targets are predominantly whole-exon.

**Dataset M1** assesses the CpG-wise measurement quality of three DNA methylation platforms: two versions of Illumina's Infinium BeadChips (the discontinued HumanMethylation450 and its successor, the MethylationEPIC) and whole genome bisulfite sequencing (WGBS) across 11 samples, including those from [@bty675-B32], [@bty675-B31]).

Lastly, **Dataset IL1** represents a true interlaboratory study where the same six biological samples are tested for *KRAS* fragment abundance of wild type (WT) and mutant (G12D) loci at twenty-one separate laboratories ([@bty675-B45]) using dPCR. For this dataset, the labwise sensitivity and precision is calculated.

Coloured text in [Figure 1](#bty675-F1){ref-type="fig"} sets the shorthand convention for technology platform/condition *i* for the remainder of this paper. For example, $b_{RNA - Seq}$ means the sensitivity *b~i~* of RNA-Seq from dataset T1 when platform *i* is RNA-Seq, *d~wholeRNA~* means the estimate of precision *d~i~* for RiboZero Whole RNA-Seq from dataset T2, and so on. Preprocessing and data accessibility for all data in this study can be found in the Sample Sources and Preprocessing section in the [Supplementary Material](#sup1){ref-type="supplementary-material"}.

2.2 The row-linear model
------------------------

We derive our method of cross-platform assessment from the description of ASTM standard E691 ([@bty675-B25]), intended for the design and analysis of interlaboratory studies on a testing method.

Consider a matrix *Z~ij~* of measurements at the same genomic locus, where the row index $i = 1,\ldots,p$ labels the whole-genome platforms (e.g. microarrays or sequencing assays) used and the column index $j = 1,\ldots,n$ labels the biological samples that are interrogated at that locus on each of the *p* platforms.

The row-linear model of the ASTM standard is $$Z_{ij} = a_{i} + b_{i}(x_{j} - \overline{x}) + d_{ij}$$ where $x_{j} = p^{- 1}\Sigma_{i}Z_{ij}$ is the average of the entries in the jth column, $a_{i} = n^{- 1}\Sigma_{j}Z_{ij}$, the average of the entries in the *i*th row is the intercept, and *b~i~* is the slope of the linear regression of $(Z_{ij},j = 1,\ldots,n)$ on ($x_{j} - \overline{x},j = 1,\ldots,n)$. Further, *d~ij~* is the residual at *x~j~* about the *i*th regression line, and the residual mean square about the *i*th fitted line is $d_{i} = {(n - 2)}^{- 1}\Sigma_{j}d_{ij}^{2}$.

Simply put, for each platform, the method regresses a set of measurements made on the *n* samples by that platform against the set of averages across the platforms of the *p* measurements on the samples.

We will refer to the parameters *a~i~*, *b~i~* and *d~i~* as the *average*, the *sensitivity* and the *precision* of the *i*th platform at the locus in question, noting that higher precision corresponds to smaller values of *d~i~*. Also, because the response variable is the sample mean of the predictor variables, we have the constraint $\Sigma_{i}b_{i} = p$, hence $\overline{b} = 1$. For most linear regressions, the residual term *d~ij~* is informative about the suitability of the fit, but in the case of row-linear model it has more direct value in that it tells us about the precision of the group of measuring devices or strategies as a whole.

A minimum of three platforms is needed to fit a row-linear model, since two degrees of freedom are needed to calculate the individual *d~i~* from the residual sum of squares. Additionally, there must be true variation in each row *i* of *Z~ij~*. Hence rows with, say, majority zero counts from RNA-Seq or fully methylated or unmethylated from whole genome bisulfite sequencing (WGBS) will produce trivial or artefactual results. Filtering steps for loci such as these are described in the Sample Sources and Preprocessing section in the [Supplementary Material](#sup1){ref-type="supplementary-material"}.

Informative extensions to the row-linear model ([@bty675-B24]) include $V(a) = {(p - 1)}^{- 1}\Sigma_{i}{(a_{i} - \overline{a})}^{2}$ and $V(b) = {(p - 1)}^{- 1}\Sigma_{i}{(b_{i} - 1)}^{2}$. (In the 1984 Mandel monograph, the method is not referred to as the row-linear model, but instead an interlaboratory study of test methods. Also, the parameters *a*, *b* and *d* are instead represented by *μ*, *β* and *η* respectively). These give per-locus estimates of concordance (low values) or discordance (high values) over all technologies assessed. Given enough platforms, further sources of inter-platform variation could be explored such as the average precision $V(d) = {(p - 1)}^{- 1}\Sigma_{i}d_{i}$, the scatter about the regression line when *b~i~* is plotted against *a~i~*, or an estimate of *z*~0~, a point along the dynamic range of the measurement at which (for some loci) the measurements converge. However, these extensions are beyond the scope of this study.

Independence between platforms is, in fact, not assumed for the row-linear model. Since the outputs are purely descriptive, any dependence between platforms will be reflected in the estimated parameters *a~i~*, *b~i~* and *d~i~*. In this sense, the row-linear model should be seen as a *summarising*, rather than an *inferential* device.

All analyses performed in this paper, and the extensions mentioned above, are easily implemented using the R package *consensus* (<https://github.com/timpeters82/consensus>). The package performs multiple locus-wise row-linear fits per dataset. Plotting functions are available to visualise individual fits, marginal distributions of *a~i~*, *b~i~* and *d~i~*, and heatmaps of the most discordant loci.

3 Results
=========

3.1 Assessment of the measurement quality of RNA expression platforms
---------------------------------------------------------------------

### 3.1.1 Dataset T1

Varying levels of concordance between gene expression levels are found from the glioblastoma data. Graphical representations of row-linear fits for two gene loci can be found in [Figure 2a and b](#bty675-F2){ref-type="fig"}, taken from dataset T1. Gene NUBP1 ([Fig. 2a](#bty675-F2){ref-type="fig"}) shows high concordance between samples, with the bundle of regression lines from the fit almost parallel, each with slope $\approx 1$ (recalling the model constraint $\overline{b} = 1$), and the points falling close to their corresponding lines. By contrast, gene HCN4 ([Fig. 2b](#bty675-F2){ref-type="fig"}) shows much more discordance between the slopes *b~i~*, with $b_{RNA - Seq}$ in particular explaining a disproportionate share of the change in expression, as well as noticeably larger residuals *d~ij~* for three out of the four platforms represented, indicating decreased precision.

![Graphical depictions of row-linear fits for genes **(a)** NUBP1 and **(b)** HCN4 from Dataset T1. **(c)** Marginal and **(d)** joint distributions for parameter *a~i~*, **(e)** marginal and **(f)** joint distributions for parameter *b~i~*, **(g)** marginal and **(h)** joint distributions for parameter *d~i~*, for the entirety of Dataset T1](bty675f2){#bty675-F2}

Broadening the perspective to all 9519 genes assayed by these four platforms, we are able to see marginal and joint distributions for *a~i~*, *b~i~*, and *d~i~* ([Fig. 2c--h](#bty675-F2){ref-type="fig"}). The platform-wise intercepts from the row-linear model *a~i~* are directly interpretable in the gene expression space; hence the distribution of *a~i~* serves as a dynamic range for the *i*th platform ([Fig. 2c](#bty675-F2){ref-type="fig"}). Joint distributions ([Fig. 2d](#bty675-F2){ref-type="fig"}) show Huex and RNA-Seq are the most correlated, U133A shows little correlation with the other platforms at lower levels of its dynamic range, and the custom Agilent microarray has quite a different dynamic range, which is a consequence of it being a two-channel array. RNA-Seq is the platform with the greatest mean sensitivity to differences in gene expression ([Fig. 2e](#bty675-F2){ref-type="fig"}), and the insensitivity of U133A to expression change at lower values suggested in [Figure 2d](#bty675-F2){ref-type="fig"} shows as a secondary mode $b_{U133A} = 0$ in [Figure 2e](#bty675-F2){ref-type="fig"}. For the other three platforms, sensitivity to expression change *b~i~* is centred around 1 ([Fig. 2f](#bty675-F2){ref-type="fig"}), indicating unimodal concordance, but with a substantial number of discordant loci. Correlations between the different *b~i~*s tend to be (but not always) negative, as the natural constraint $\overline{b} = 1$ renders sensitivity between platforms competitive. As the variation *V*(*b*) increases---that is, as the cross-platform sensitivity becomes more discordant---the RNA-Seq begins to explain a disproportionate share of the cumulative *b~i~* ([Supplementary Fig. S1](#sup1){ref-type="supplementary-material"}). Cross-platform precision *d* shows similar marginal means for RNA-Seq, Agilent and Huex, but lower for that of U133A, indicating higher precision for this platform ([Fig. 2g](#bty675-F2){ref-type="fig"}). However, given that U133A also shows the lowest sensitivity ([Fig. 2e](#bty675-F2){ref-type="fig"}), from a platform design perspective there may have been a trade-off between risk and reward in detecting changes in gene expression that has now been surmounted by more recent technologies. Given its greater overall sensitivity and competitive precision, RNA-Seq is the superior platform from dataset T1.

In addition to comparing distributions of platform sensitivity and precision to each other, we also examined whether these platforms showed any relative gene-specific biases by plotting CDS length (SFs 2a and 2b) and GC content (SFs 2c and 2d) against *b~i~* and *d~i~*. All effects of CDS length are mild to non-existent, including from the remaining transcription datasets (data not shown). There is a slight suggestion of relatively decreased precision of Huex and RNA-Seq at short CDSs (SF 2b). GC content has a greater effect, with mild to moderate relative decrease in sensitivity on the microarrays, offset by an increase for RNA-Seq (SF 2c). In addition, the three array platforms, especially Huex, struggle with maintaining relative precision assaying genes with low GC-content, with RNA-Seq proving to be the most robust (SF 2d).

### 3.1.2 Datasets T2, T2A and T2B

Similar to dataset T1, RNA-Seq has greater sensitivity than microarrays, this time with both strategies (PolyA+ and WholeRNA) clustering together, and the two microarray platforms also doing so at a lower *b~i~* ([Fig. 3a](#bty675-F3){ref-type="fig"}). While the HuGene array shows similar precision to the distributions from RNA-Seq, the Human Transcriptome Array shows a clearly superior precision ([Fig. 3b](#bty675-F3){ref-type="fig"}). Remaining marginal and joint distributions for *a~i~*, *b~i~*, and *d~i~* for dataset T2 can also be found in SF 3, and those for datasets T2A and T2B can be found in SFs 4 and 5 respectively. When the HuGene array and HTA are broken down into their exonic and sub-exonic features in datasets T2A and T2B, the superior precision of HTA to RNA-Seq is maintained (SF 5e), but the HuGene array shows both inferior sensitivity and precision to RNA-Seq (SFs 4c and 4e).

![Marginal distributions of **(a)***b~i~* and **(b)***d~i~* for dataset T2. Boxplots separating loci into coding and noncoding targets over all platforms for **(c)** dataset T2 sensitivity, **(d)** dataset T2 precision, **(e)** dataset T2B sensitivity and **(f)** dataset T2B precision](bty675f3){#bty675-F3}

Turning to gene-specific biases from dataset T2, we see the same loss of sensitivity with increasing GC content on the microarray platforms, with the compensatory increase from RNA-Seq (SF 6a), as we saw in dataset T1. We also see the same increased robustness to this domain of the precision estimate for RNA-Seq, whereas precision is slightly lower for low GC content loci in microarrays (SF 6b).

For both genewise (dataset T2) and exon/sub-exon (dataset T2B) target levels, HTA annotation lists targets that are either coding or noncoding, and we observe effects (calculated using Cohen's *D*: the difference of means divided by the pooled standard deviation) between these locus types. Here (and for the rest of the paper) we use Cohen's *D* to report effect size, capitalising to avoid confusion with precision *d~i~*. The R package "effsize" ([@bty675-B39]) was used for all calculations. At the gene level, microarray sensitivity is greater for coding loci than for noncoding, and the opposite is true for RNA-Seq ([Fig. 3c](#bty675-F3){ref-type="fig"}). Precision is superior at coding loci on all platforms, except for HuGene, which evinces no effect ([Fig. 3d](#bty675-F3){ref-type="fig"}). However, for dataset T2B, these effects are reversed on sensitivity and precision across all three platforms, albeit to a smaller magnitude in all cases ([Fig. 3e and f](#bty675-F3){ref-type="fig"}). For example, noncoding loci show greater sensitivity than coding loci when assayed on HTA for dataset T2B ([Fig. 3e](#bty675-F3){ref-type="fig"}).

3.2 Assessment of the measurement quality of DNA methylation platforms
----------------------------------------------------------------------

### 3.2.1 Dataset M1

As with the previous two datasets, we were able to apply a row-linear model to a suite of DNA methylation platforms containing both microarrays and sequencing assays. Perhaps unsurprisingly, the distributions of *a~i~*, *b~i~* and *d~i~* ([Fig. 4](#bty675-F4){ref-type="fig"}) for 450 K and EPIC are extremely similar, owing to identical probe chemistry. (Joint distributions of these can be found in SF 7. The shrunk hypomethylated mode in [Figure 4a](#bty675-F4){ref-type="fig"} is due to the filtering of CpG sites as outlined in the Sample Sources and Preprocessing section of the [Supplementary Material](#sup1){ref-type="supplementary-material"}, where CpG loci were discarded if they had at least 8 out of 11 samples completely unmethylated in WGBS.). However, there are a very small number of probes for which the signal is highly discrepant between the two platforms, and in the majority of these cases WGBS can provide clues as to which platforms measurements are more accurate. Two extreme examples, one for each array platform, are shown in [Figure 4d and e](#bty675-F4){ref-type="fig"}. These were discovered by filtering for large values of *V*(*a*) for this dataset. However, WGBS is unable to do this in a general way across all CpG sites with respect to sensitivity, showing little favour to either platform in the DeFinetti plot in [Figure 4f](#bty675-F4){ref-type="fig"}. WGBS itself is superior to the arrays in sensitivity ([Fig. 4b and f](#bty675-F4){ref-type="fig"}), but has lower precision ([Fig. 4c](#bty675-F4){ref-type="fig"}). This is expected, however, given that WGBS is clearly the odd platform from a consensus highly influenced by very similar arrays.

![Marginal distributions for **(a)** parameter *a~i~*, **(b)** parameter *b~i~* and **(c)***d~i~*, for the entirety of Dataset M1. Graphical depictions of row-linear fits for array-discordant CpG sites for which WGBS data favours **(d)** the EPIC array and **(e)** the 450K array. **(f)** DeFinetti diagram showing the proportions of *b~i~* described by the three platforms in Dataset M1. We show backtransformed axes to the more interpretable methylation domain (0, 1) in **(a)**, **(d)** and **(e)**](bty675f4){#bty675-F4}

To explore the effects of array normalisation, we also fit a separate set of row-linear models to the raw data, calculating methylation "beta" ratios from the raw array signal and transforming them to *M*-values as outlined for WGBS in the Sample Sources and Preprocessing section in the [Supplementary Material](#sup1){ref-type="supplementary-material"}. Illumina arrays have two separate probe types with different biochemistries, with Type I probes assuming a uniform methylated epitype across the length of the 50 base hybridisation locus, and Type II probes using a single-base extension at the 3' end to circumvent this assumption ([@bty675-B6]). A clear decrease in precision (increase in *d~i~*) is seen in the non-normalised Type I probes, compared to Type II on both 450 K and EPIC ([Fig. 5a](#bty675-F5){ref-type="fig"}). Similarly, a considerable increase in precision is apparent with an increase of the total raw intensity (M + U) from Type II probes ([Fig. 5b](#bty675-F5){ref-type="fig"}). The normalisation procedure `preprocessFunnorm()` ([@bty675-B12]) does an excellent job at correcting these discrepancies in *d~i~*, as shown in [Figure 5c and d](#bty675-F5){ref-type="fig"}.

![Effect of array normalisation on Dataset M1. Precision of raw 450K and EPIC data **(a)** split by Type I and Type II probes and **(b)** total intensity (methylated + unmethylated channel) of Type II probes, and (**c** and **d**) the same values post-normalisation](bty675f5){#bty675-F5}

Elements particular to the human genome may interfere with the methylation measurement of CpG loci. For example, a small decrease in sensitivity is noted for when probe hybridisation overlaps a repeat region ([Fig. 6a](#bty675-F6){ref-type="fig"}), as per [@bty675-B27]. Hence it is likely that the methylation state of the repeated CpG locus is non-uniform. Additionally, cross-hybridisation is a known confounder of microarray technology, where probes designed to hybridise to an intended genomic site instead hybridise to an off-target site with high homology ([@bty675-B7]; [@bty675-B8]). It is known that Illumina array signals are prone to potential cross-hybridising events, based on in silico alignment of probe sequences to the human reference ([@bty675-B8]; [@bty675-B32]). Unlike the expression arrays in dataset T2, the hybridisation is intended to have one target only (as opposed to a composite set of targets over a gene locus), and so we are able to elucidate the off-target effects more precisely. A subset of these probes for which homology is 47/50 base pairs or higher is listed in [@bty675-B32]. We find that the sensitivity these of probes is blunted in comparison to probes for which no high-level homology was found ([Fig. 6b](#bty675-F6){ref-type="fig"}), and this effect is more severe on the EPIC array (*D *=* *0.73) than it is on the 450 K array (*D *=* *0.43). To further characterise the degree of off-target hybridisation, we then posited that the signal from these genomically promiscuous probes could be expressed as a linear combination of the methylation levels from the off-target sites, as well as the target site. This would simulate the competitive homology between all potential binding sites for the given probe. The WGBS data is useful for this since its measurements do not have a cross-reactive bias, and that we have methylation measurements for the off-target CpG sites that are not assayed by the array technology. For each individual CpG site flagged as having a potentially cross-reactive probe on both 450 K and EPIC arrays, we fit two individual LASSO ([@bty675-B38]) sparse regression models with response either $y_{i} = Z_{450K}$ or *y~i~* = *Z~EPIC~* from the measurement matrix *Z~ij~*, and set the predictor matrix $x^{i} = {(Z_{WGBS},A_{1},\ldots,A_{m})}^{T}$ where *A* is a *m*x*n* matrix of WGBS methylation measurements from the corresponding CpG loci of the off-target hybridisation sites. The corresponding estimated regression coefficients $\hat{\beta} = ({\hat{\beta}}_{target},{\hat{\beta}}_{off - target_{1}},\ldots,{\hat{\beta}}_{off - target_{m}})$ were calculated. [Figure 6c](#bty675-F6){ref-type="fig"} plots array sensitivities $b_{450K}$ and *b~EPIC~* against ${\hat{\beta}}_{target}$ for all known cross-reactive probes/CpG loci. Non-zero target coefficients correlate well with the sensitivity of the array, indicating that $b_{450K}$ and *b~EPIC~* serve as reasonable predictors of the degree of target homology. However, many coefficients are at or very close to zero. For these probes, this means that the entirety of their signals can be explained by a linear combination of the methylation values from their cross-hybridising genomic sites, and thus are unlikely to be measuring the target site at all. To check this was not an artefact of the LASSO fits themselves, we then randomly selected an identical number (*n *=* *11 646) of *non*-cross-hybridising probes from dataset M1 and also fit a LASSO model for each one, substituting their matching WGBS values for the original *Z~WGBS~* but retaining the *same* list of *A* matrices used for the cross-hybridising LASSO fits. The resulting ${\hat{\beta}}_{target}$s are higher than those from the cross-hybridising probes ([Fig. 6d](#bty675-F6){ref-type="fig"}), providing strong evidence for competitive homology having a detrimental effect on Infinium probe sensitivity. A complete list of the LASSO coefficients for the target site, and sum of coefficients from the off-target sites for cross-hybridising probes can be found in [Supplementary Table S1](#sup2){ref-type="supplementary-material"}, for both 450 K and EPIC arrays.

![Effect of **(a)** repeat regions and **(b)** cross-hybridisation on array sensitivity from dataset M1. **(c)** Sensitivity of cross-hybridising probes against the LASSO coefficient ${\hat{\beta}}_{target}$ of target WGBS values from sparse linear modelling. **(d)** Effect of cross-hybridisation on the predictive capacity of WGBS measurements for their matched microarray measurements, via LASSO. **(e)** Precision of WGBS against mean coverage of the samples, for individual CpG loci](bty675f6){#bty675-F6}

Returning to datasets T2 and T2A, the HuGene annotation also describes targets that potentially cross-hybridise to off-target sites. However, there are negligible differences in sensitivity between these targets and the remainder (SFs 8a and 8b). One explanation for this is that the measurements on the HuGene arrays are composite, containing a mixture of probes that potentially cross-hybridise, and those that don't. It may be that the cross-hybridising component of the signal is too weak to evince any systematic bias for this particular dataset.

Lastly, the question of minimum WGBS sequencing coverage for detection of methylation differences is a practical consideration for many labs, and estimates at characterising this figure for a given methylation shift size have been made ([@bty675-B46]). Under binomial assumptions of simulated data, higher coverage results in a lower variability of the estimate when the methylation level is known. In other words, the measurement is more precise. This is reflected in mildly decreasing *d~i~* as the mean WGBS coverage increases ([Fig. 6e](#bty675-F6){ref-type="fig"}). Notably, the loess curve carries on decreasing at higher levels of coverage, even up to 1000x, evincing no "point of saturation", even though the data points are sparse.

3.3 An interlaboratory test on DNA abundance measurements
---------------------------------------------------------

### 3.3.1 Dataset IL1

Finally, to demonstrate the utility originally intended for the row-linear model, we perform a true interlaboratory test that assesses measurement quality not across technologies, but across geographical testing sites. The measurements used are log-transformed fragment concentrations (copies/μL in reaction) of 2 genotypic forms of human *KRAS* assayed using digital PCR (dPCR) on 6 biological samples from [@bty675-B45].

To test whether a site effect was indeed present, independent of biological variation, we constructed row-linear fits using the set of $i \in \left\{ 1,2,\ldots,21 \right\}$ as numbered candidate laboratories to be compared. Deviant testing sites include laboratories 17 and 21 with respect to sensitivity ([Fig. 7a](#bty675-F7){ref-type="fig"}), and laboratories 5 and 21 with respect to lower precision ([Fig. 7b](#bty675-F7){ref-type="fig"}), with laboratories 1 and 4 showing the greatest measurement precision when compared to the consensus. These results are somewhat consonant with the reproducibility analysis in the original manuscript, in that laboratories 17 and 21 (as well as laboratory 2) are singled out for likely droplet misclassification. In addition, laboratory 21 has the greatest number of deviant analysis parameters of all testing sites (i.e., laboratory conditions, [Supplementary Table S3](#sup4){ref-type="supplementary-material"} from [@bty675-B45]) including unique models of the PCR plate sealer and thermal cycler, potentially explaining its position as the most outlying laboratory.

![Scatterplots depicting **(a)***b~i~* and **(b)***d~i~* of twenty-one laboratories for both *KRAS* genotype abundances, from Dataset IL1. Number plotted denotes laboratory ID](bty675f7){#bty675-F7}

4 Discussion
============

We have shown the row-linear model has the ability to empirically assess the sensitivity and precision of genomic platforms, given a sufficient corpus of variable samples. This model is highly versatile in that it not only allows direct comparisons of platforms with each other, but can be used to assess locus-specific biases and characteristics particular to both the platforms themselves and the genome they are measuring. Importantly, it assesses the measurement quality of each platform *independent of the biological variation in the data*. In addition, it can be used as a screening procedure to identify platforms with deviant measurements, and subsequently remove them prior to using applications that leveraging cross-platform information for biological purposes ([@bty675-B37]; [@bty675-B40]; [@bty675-B42]).

Most effects we have shown are mild, or limited to a small subset of loci, so the results shown herein ought to be read with caution. Interpretation of trends as tendencies, rather than categorical biases, is advisable. The consensus improves as more technologies are included in the row-linear fit, since it is less susceptible to skewing due to measurement from a deviant technology. Positive correlations between the respective *d~i~*s (for example, in [Fig. 2h](#bty675-F2){ref-type="fig"}) are indicative that the ease with which quantification can be made varies from locus to locus---likely a result of stochastic "burstiness" ([@bty675-B34])---and this variation is somewhat preserved across platforms. Platforms such as WGBS can be seen as higher-risk, higher-reward technologies, given their extreme ranks in both sensitivity and precision. Some trends are quite clear, such as an anticorrelation of relative microarray sensitivity with GC content, which is likely due to differing amplification efficiencies ([@bty675-B2]; [@bty675-B10]). Plainly, RNA-Seq outperforms all microarrays in terms of sensitivity to changes in transcription and robustness to GC content. However, its measurement quality is less clear when it comes to precision. An anticorrelative effect can be seen between *a~i~* and *d~i~* on all RNA-Seq platforms (data not shown), though this is likely an artefact of the variance stabilisation via log transformation of counts, which may be suboptimal. Most of the library sizes used in this study (see [Supplementary Tables S2](#sup3){ref-type="supplementary-material"} and [S3](#sup4){ref-type="supplementary-material"}) are below those recommended for analysis of differential expression ([@bty675-B23]), speaking to the lack of stability of quantification estimates when overall count pileup is low. The HTA's superior precision at both the gene and exon level supports previous work, where stochastic variability of the signal was found to be higher in RNA-Seq than from this array ([@bty675-B28]). No appreciable differences were observed between the two RNA-Seq strategies in datasets T2, T2A and T2B in terms of direct comparison. When comparing coding and noncoding loci, Whole RNA-Seq shows a smaller divergence ([Fig. 3c and d](#bty675-F3){ref-type="fig"}), which relates to earlier work showing this strategy shows less variability than PolyA+ for quantifying some noncoding RNAs ([@bty675-B13]). The reasons for the reversal of effect between coding and noncoding RNAs from dataset T2 to T2B remain elusive; however this may be a consequence of the design of the HTA, giving more emphasis to quantifying canonical coding loci at the gene level, but removing this emphasis at the more granular exon level.

In terms of methylation, we have shown that a subset of potentially cross-hybridising probes on Illumina arrays show a lower sensitivity to change, as do probes known to hybridise to repeat regions. Both phenomena result in heterogeneous sources of signal intensity which, if hybridisation patterns are consistent, would not hinder the precision of the signal, but rather its sensitivity to methylation change compared to other loci, which is precisely what we see. Further evidence for this is gained from modelling the off-target methylation measurements from WGBS as predictors of the microarray measurements. The increased susceptibility of EPIC to blunted sensitivity via cross-hybridisation is without categorical explanation, but may be related to the fact that the overall intensities (M + U) of the EPIC arrays used in this study are, on average, only $\sim 70\%$ as strong as that of that of 450 K, which may indicate fewer total hybridisation events for this technology. We have also shown that the row-linear model can be powerful tool in assessing current and future microarray normalisation procedures, as evidenced from the methylation results.

From the results taken from interlaboratory test on Dataset IL1, we can conclude that known deviations from consensus protocols can result in discordance of measurement between testing sites. A more standardised testing procedure, where intentional differences in protocol are implemented, replicated and blocked properly across all sites prior to row-linear modelling of their measurements would further elucidate the effect of such deviations.

To improve the characterisation of the biases outlined in this paper, a broader collection of platforms and samples will be needed. For example, the quality assessment of both transcription and methylation sequencing assays would be clarified by sequencing these (and other) samples across a range of library sizes and coverage depths. Data from the SEQC/MAQC-III consortium ([@bty675-B35]) would have been ideal to use for this paper, but the limited number of samples (*n *=* *4) unfortunately precludes us from applying an informative row-linear fit.

As suggested from our discussion of Dataset IL1, applications of the row-linear model need not be restricted to different technologies, either. Potential biases from reagent concentrations, ambient laboratory temperature and humidity, and temporal and geographical variation are all able to be characterised by the row-linear model in the same fashion exemplified here, providing matched, homogenous aliquots of nucleic acid are distributed across all conditions. Given enough biological and technological replicates, a growing, dynamic repository of contributions sourced from throughout the world (in the vein of, for example, *recount2* ([@bty675-B9])) would allow calculation of increasingly stable consensus estimates for sensitivity and precision. This is a conceivable empirical alternative to a static gold-standard benchmark of measurement. Through such an infrastructure, scientists will have increased confidence in the reproducibility of their results.
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